Surveillance of Respiratory Pathogens and Brand-Specific Vaccine Effectiveness in Adults Hospitalised with SARI: An Observational Study

01/03/2024
28/09/2026
EU PAS number:
EUPAS1000000035
Study
Ongoing
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS1000000035

Study ID

1000000035

Official title and acronym

Surveillance of Respiratory Pathogens and Brand-Specific Vaccine Effectiveness in Adults Hospitalised with SARI: An Observational Study

DARWIN EU® study

No

Study countries

Canada
Germany
Spain
United Kingdom

Study description

This is a European, non-interventional study to estimate the effectiveness of vaccines against respiratory syncytial virus (RSV). Of interest is the effectiveness against hospitalisation with severe acute respiratory infection (SARI) caused by RSV.

- - Update 01 Sep 2026- -
From 01 Sep 2026 (start of the id.DRIVE epidemiological year 2026-2027), the three id.DRIVE master study protocols (EUPAS1000000012, EUPAS42328, and EUPAS1000000035) are merged into one common master protocol (EUPAS1000000012; V3.0 02 Mar 2026).
New, common study title:
Surveillance of Respiratory Pathogens and Brand-Specific Vaccine Effectiveness in Adults Hospitalised with SARI: An Observational Study
This means that the respiratory pathogen surveillance protocol (EUPAS1000000012; ongoing) now also incorporates the RSV vaccine effectiveness (EUPAS1000000035; ongoing; RSV VE module) and COVID-19 vaccine effectiveness (EUPAS42328; paused; CVE module) studies. EUPAS42328 and EUPAS1000000035 are updated accordingly in this register (the reader of those two is now referred to EUPAS1000000012).

Study status

Ongoing
Research institutions and networks

Institutions

Imperial College London
United Kingdom
First published:
01/02/2024
Institution Educational Institution
Valencia Hospital Network for the Study of Influenza and Other Respiratory Viruses (VAHNSI)

Universitätsklinikum Ulm
Charité - Universitätsmedizin Berlin
Universitätsklinikum Düsseldorf
Universitätsklinikum Essen

Manchester University NHS Foundation Trust (MFT)
NHS Lothian

The Ottawa Hospital
The Toronto Invasive Bacterial Diseases Network (TIBDN)
Calgary Corridor Hospitals

Networks

id.DRIVE (former COVIDRIVE)
Austria
Belgium
Canada
Croatia
Czechia
Denmark
France
Germany
Iceland
Italy
Poland
Romania
Spain
United Kingdom
First published:
04/05/2026
Network
ENCePP partner

Contact details

Kaatje Bollaerts

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pfizer
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable